These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17041638)

  • 1. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells.
    Numbenjapon T; Serrano LM; Singh H; Kowolik CM; Olivares S; Gonzalez N; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Leukemia; 2006 Oct; 20(10):1889-92. PubMed ID: 17041638
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
    Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
    Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering GVL through T cell gene transfer.
    Jensen MC
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):5. PubMed ID: 18162214
    [No Abstract]   [Full Text] [Related]  

  • 4. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
    Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
    Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies.
    Tam CS
    Leuk Lymphoma; 2013 Feb; 54(2):215-6. PubMed ID: 22950939
    [No Abstract]   [Full Text] [Related]  

  • 6. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
    Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
    PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
    Loskog A; Giandomenico V; Rossig C; Pule M; Dotti G; Brenner MK
    Leukemia; 2006 Oct; 20(10):1819-28. PubMed ID: 16932339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
    Oh I; Oh Y; Ohmine K
    Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
    Numbenjapon T; Serrano LM; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Exp Hematol; 2007 Jul; 35(7):1083-90. PubMed ID: 17588477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
    Maus MV; Thomas AK; Leonard DG; Allman D; Addya K; Schlienger K; Riley JL; June CH
    Nat Biotechnol; 2002 Feb; 20(2):143-8. PubMed ID: 11821859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting high-grade B cell lymphoma with CD19-specific T cells.
    Lehmann FM; Maurberger A; Feicht S; Helm F; Ladinig C; Kieback E; Uckert W; Kammertöns T; Kremmer E; Mautner J; Gerbitz A; Bornkamm GW
    Int J Cancer; 2014 Sep; 135(5):1153-64. PubMed ID: 24500882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to put the CAR-T before the horse.
    Jacobson CA; Ritz J
    Blood; 2011 Nov; 118(18):4761-2. PubMed ID: 22053170
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.
    Landmeier S; Altvater B; Pscherer S; Meltzer J; Sebire N; Pule M; Vera J; Hotfilder M; Juergens H; Vormoor J; Rossig C
    Leukemia; 2010 May; 24(5):1080-4. PubMed ID: 20220773
    [No Abstract]   [Full Text] [Related]  

  • 17. CAR T cells: driving the road from the laboratory to the clinic.
    Cheadle EJ; Gornall H; Baldan V; Hanson V; Hawkins RE; Gilham DE
    Immunol Rev; 2014 Jan; 257(1):91-106. PubMed ID: 24329792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
    Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
    Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are all chimeric antigen receptors created equal?
    Park JH; Brentjens RJ
    J Clin Oncol; 2015 Feb; 33(6):651-3. PubMed ID: 25605860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.